OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Comparative Effectiveness Research is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Cost–effectiveness of pembrolizumab for second-line treatment of esophageal squamous cell carcinoma patients with a combined positive score of 10 or more	127
MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy	46
Acute effects of resistance exercise with blood flow restriction on cardiovascular response: a meta-analysis	41
Economic burden of sickle cell disease in the United States: a retrospective analysis of a commercial insurance database	38
Effect of home-based exercise programs with e-devices on falls among community-dwelling older adults: a meta-analysis	36
Postoperative outcomes and anesthesia type in total knee arthroplasty in patients with obstructive sleep apnea	28
Journal of Comparative Effectiveness Research : 2022 year in review	25
An observational cohort study of pelvic floor photobiomodulation for treatment of chronic pelvic pain	24
Smart connected insulin dose monitoring technologies versus standard of care: a Canadian cost–effectiveness analysis	24
Engaging veterans in the research process: a practical guide	22
Atezolizumab with chemotherapy in first-line treatment for metastatic urothelial cancer: a cost–effectiveness analysis	22
Corrigendum	21
Effectiveness and safety of asfotase alfa for people with hypophosphatasia: a plain language summary of three studies	21
Discharges against medical advice and 30-day healthcare costs: an analysis of commercially insured adults	19
Cost–effectiveness analysis of a resource-intensive approach versus minimally invasive strategy for high-risk transcatheter aortic valve replacement patients	19
Costs associated with nonalcoholic steatohepatitis disease progression in Medicare patients: a retrospective cohort study	19
Impact of surgical complications on hospital costs and revenues: retrospective database study of Medicare claims	18
Impact of clinical research coordinators on research output in orthopedic surgery	18
Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-naïve people with HIV-1: a systematic literature review and network meta-analysis	18
Ravulizumab in adults and children with atypical hemolytic uremic syndrome: a plain language summary of three studies	17
The cost–effectiveness of pegcetacoplan in complement treatment-naïve adults with paroxysmal nocturnal hemoglobinuria in the USA	17
Cost of disease progression among US patients with human epidermal growth factor receptor 2-positive metastatic breast cancer	15
Healthcare utilization and costs following molecular diagnostic testing among patients with vaginitis	15
Time-limited reimbursement and Temporary Access Process for early access to oncology treatments in Canada: a perspective based on the epcoritamab experience	15
Clinical manifestations and healthcare utilization before diagnosis of transthyretin amyloidosis	14

Clinical assessment of the potential use of a novel single-dose prefilled injection device for the administration of Acthar Gel in children: a narrative review	14
Bayesian hierarchical model-based network meta-analysis to overcome survival extrapolation challenges caused by data immaturity	13
Letter in reply	13
Lessons on the use of real-world data in medical device research: findings from the National Evaluation System for Health Technology Test-Cases	12
Cost–effectiveness analysis of prolonged-release fampridine to treat walking disability of multiple sclerosis in China	12
Corrigendum	12
EU HTA Joint Clinical Assessment: are patients with rare disease going to lose out?	12
A real-world analysis of antidepressant medications in US veterans aged 60 years and older: a comparative analysis	11
Augmenting external control arms using Bayesian borrowing: a case study in first-line non-small cell lung cancer	11
Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients	11
R WE ready for reimbursement? A round up of developments in real-world evidence relating to HTA: part 3	11
Real-world ePRO use and clinical outcomes using electronic patient-reported symptom monitoring for patients with advanced non-small-cell lung cancer receiving first-line pembrolizumab	11
Cost–effectiveness of lung cancer screening with volume computed tomography in Portugal	11
Validity of comorbidity adjustment scores in estimating in-hospital mortality in individual subgroups of race/ethnicity	11
Healthcare costs and resource utilization of patients with chronic post-traumatic stress disorder: a retrospective US claims analysis of commercially insured patients	10
Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema	10
Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type 2 diabetes in Canada	10
Increasing transparency in indirect treatment comparisons: is selecting effect modifiers the missing part of the puzzle? A review of methodological approaches and critical considerations	10
Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer	9
Effectiveness of tisagenlecleucel versus real-world standard of care in relapsed/refractory follicular lymphoma	9
Real-world weight changes in people with HIV-1 at risk of weight gain (female, Black or Hispanic) switching from integrase strand transfer inhibitors	9
Preferences, satisfaction and decision-making processes in osteoporosis treatment: a systematic review of the literature	9
Characterization of medical device randomized controlled trials with adaptive designs	9
Evaluation of patient/caregiver and healthcare provider knowledge, attitudes and behavior for safety and use of pexidartinib	9
Ravulizumab for adults with generalized myasthenia gravis: a plain language summary of three studies	9
To replicate or not to replicate? Insights and interpretations from a randomized trial duplication initiative	9
Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol	9
Comparison of intravenous versus topical tranexamic acid in primary total hip arthroplasty: a systematic review and meta-analysis of ten randomized trials	8
Evidence-based public policy making for medicines across countries: findings and implications for the future	8
How the use of standardized protocols may paradoxically worsen disparities for safety-net hospitals	8
Letter to the editor: network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema	8
Diversity in clinical trial inclusion for peripheral artery disease lower extremity endovascular interventions: a systematic review protocol	8
The triple win – implementation science benefits patients, healthcare systems and industry alike	8
Cost–utility analysis of single nucleotide polymorphism panel-based machine learning algorithm to predict risk of opioid use disorder	8
Review and estimation of disutility for joint health states of severe and nonsevere hypoglycemic events in diabetes	8
Comparison of Enterprise stent 2 with 1 in assisting coiling of ruptured aneurysms: a real-world study	8
Impact analysis of expanding narrow-spectrum antibiotic use for children with ear, sinus and throat infections	8
Dependent censoring bias assessment using inverse probability of censoring weights: Type 2 diabetes mellitus risk in patients initiating bisoprolol versus other antihypertensives in a Clinical Practic	8
Healthcare resource utilization and costs in pediatric pulmonary arterial hypertension in a third-level hospital in Mexico	7
Overall survival in the UK in mycosis fungoides or Sézary syndrome cutaneous T-cell lymphoma: comparative effectiveness of mogamulizumab versus current standard of care	7
The effects of Pilates on pain, functionality, quality of life, flexibility and endurance in lumbar disc herniation	7
Are indirect comparisons for treatments in migraine necessitas? Many inevitable challenges to overcome	7
Access in all areas? A round up of developments in market access and health technology assessment: part 1	7
Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in colorectal cancer: a meta-analysis	7
Economic analysis of the use of video laryngoscopy versus direct laryngoscopy in the surgical setting	7
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 10	7
Single-arm oncology trials and the nature of external controls arms	7
Impact of COVID-19 on chronic pain structures: data from French national survey	7
COVID-19 clinical trials: who is likely to participate and why?	7
Corrigendum	7

Navigating adalimumab biosimilars: an expert opinion	6
Expanding the learning health system model to be health literate	6
Evaluating real-world COVID-19 vaccine effectiveness using a test-negative case–control design	6
The impact of lower limb chronic venous disease on quality of life: patient and physician perspectives	6
Cost–effectiveness of empagliflozin versus weekly semaglutide as add-on therapy for Type 2 diabetes	6
Once-nightly sodium oxybate (FT218) improved symptoms of disrupted nighttime sleep in people with narcolepsy: a plain language summary	6
Uricemia in the acute phase of myocardial infarction and its relation to long-term mortality risk	6
Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchers	6
A systematic review of discounting in national health economic evaluation guidelines: healthcare value implications	6
Cost–effectiveness of ensartinib for patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer in China	6
An economic evaluation of teledermatology care delivery for chronic skin diseases	6
Use of transportability methods for real-world evidence generation: a review of current applications	6
The health-related quality of life of patients with a benign gynecological condition: a 2-year follow-up	6
Burden of illness for patients with primary biliary cholangitis: an observational study of clinical characteristics and healthcare resource utilization	6
Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma	6
Assessing the change in disease severity based on depressive symptoms in real-world psoriasis patients	6
An evaluation of stakeholder engagement in comparative effectiveness research: lessons learned from SWOG S1415CD	6
An impact evaluation of an education bundle for patients at risk of developing venous thromboembolism	6
Treatment goals for rheumatoid arthritis: patient engagement and goal collection	6
Does off-hours endoscopic hemostasis affect outcomes of nonvariceal upper gastrointestinal bleeding?	6
Comparative effectiveness research in COVID-19 using real-world data: methodological considerations	6
Economic impact of reduced postoperative visits after inflatable penile prosthesis implantation	5
Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US	5
COVID-19 complications in males and females: recent developments	5
Steroid switching in dystrophinopathy treatment: a US chart review of patient characteristics and clinical outcomes	5
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 15	5
Mapping methods gaps between EU joint clinical assessments and local health technology assessment decision-making: an environmental scan of guidance in select EU markets and harmonization challenges	5
Application of quantitative bias analysis for unmeasured confounding in cost–effectiveness modelling	5
In-hospital mortality in amyloid light chain amyloidosis: analysis of the Premier Healthcare Database	5
Vaginal laser therapy for gynecologic conditions: re-examining the controversy and where do we go from here	5
R WE ready for reimbursement? A round up of developments in RWE relating to health technology assessment: part 2	5
A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib	5
A value-based budget impact model for dronedarone compared with other rhythm control strategies	5
Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data	5
Letter in Reply: indirect comparison of quality-of-life scores between patients with advanced breast cancer receiving palbociclib and abemaciclib in combination with fulvestrant	5
Navigating the unknown: how to best ‘reflect’ standard of care in indications without a dedicated treatment pathway in health technology assessment submissions	5
Structural hemodynamic valve deterioration durability of RESILIA-tissue versus contemporary aortic bioprostheses	5
Economic burden of early-stage non-small-cell lung cancer: an assessment of healthcare resource utilization and medical costs	5
Robotic-assisted total hip arthroplasty: an economic analysis	5
QDOT MICRO™ versus THERMOCOOL ^® SMARTTOUCH™ and THERMOCOOL SMARTTOUCH ^® Surround Flow in radiofrequency ablation of paroxysmal atr	5
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 4	4
The effect of midodrine on lactate clearance in patients with septic shock: a pilot study	4
Respiratory and nonrespiratory COVID-19 complications in patients with obesity: recent developments	4
Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis	4
Visualizing the target estimand in comparative effectiveness studies with multiple treatments	4
Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data inROS1+ NSCLC	4
Why, whether and how to use high-flow nasal therapy in acute exacerbations of chronic obstructive pulmonary disease	4
Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting	4
Safety and effectiveness of intranasal esketamine for treatment-resistant depression: a real-world retrospective study	4
Semaglutide treatment for obesity in teenagers: a plain language summary of the STEP TEENS research study	4
Clinical and economic implications of focal dissection treatment following percutaneous transluminal angioplasty of the superficial femoral artery: an exploratory analysis based on the TOBA II Study	4
Cost–effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma	4
Budget impact analyses of hemoglobin A1c and lipid panel point-of-care testing with Afinion™ 2 in Canada and Italy	4
Budesonide/formoterol versus salmeterol/fluticasone for asthma in children: an effectiveness and safety analysis	4
An international observational study assessing conservative management in hemorrhoidal disease: results of CHORALIS (aCute HemORrhoidal disease evALuation International Study)	4
Impact of the COVID-19 pandemic on healthcare resource utilization across selected disease areas in the USA	4
Impact analysis of expanded access to ketamine for treatment-resistant depression	4
How pharma can amplify product value with implementation science	4
Micronized purified flavonoid fraction in the treatment of hemorrhoidal disease	4
Impact of comparative effectiveness research on Medicare coverage of direct oral anticoagulants	4
Evaluation of inpatient and emergency department healthcare resource utilization and costs pre- and post-nusinersen for the treatment of spinal muscular atrophy using United States claims	4
The need to consider market access for pharmaceutical investment decisions: a primer	4
A review of stakeholder recommendations for defining fit-for-purpose real-world evidence algorithms	4
Comparing the efficacy of cipaglucosidase alfa plus miglustat with other enzyme replacement therapies for late-onset Pompe disease: a network meta-analysis utilizing patient-level and aggregate data	4
Val (EU) xit: do we need an international ISPOR value flower?	4